ライフサイエンスコーパス: parainfluenza virus type 3

1 lymphocytic choriomeningitis virus and human parainfluenza virus type 3.

2 ion, which was 40-fold lower than that of WT parainfluenza virus type 3.

3 Human parainfluenza virus type 3, a mildly cytopathic virus th

4 s of a live-attenuated vaccine candidate for parainfluenza virus type 3, an enveloped RNA virus that

5 For human parainfluenza virus type 3 and many other paramyxoviruse

6 tial innate antiviral response against human parainfluenza virus type 3 and respiratory syncytial vir

7 yncytial virus, human metapneumovirus, human parainfluenza virus type 3, and measles virus, and highl

8 fever (SF) and Kansas (Ka) strains of bovine parainfluenza virus type 3 (BPIV3) are restricted in the

9 The Kansas strain of bovine parainfluenza virus type 3 (BPIV3) is 100- to 1,000-fold

10 Bovine parainfluenza virus type 3 (bPIV3) is being evaluated as

11 raminidase (HN) glycoprotein genes of bovine parainfluenza virus type 3 (BPIV3) to its restricted rep

12 to evaluate the antibody responses to bovine parainfluenza virus type 3 (bPIV3) vaccination in young

13 doses of an intranasal vaccine using bovine parainfluenza virus type 3 (bPIV3).

14 Treatment of parainfluenza virus type 3 bronchiolitis and pneumonia i

15 uses, including the childhood pathogen human parainfluenza virus type 3, enter host cells by fusion o

16 explores the binding and entry into cells of parainfluenza virus type 3, focusing on how the receptor

17 The envelope of human parainfluenza virus type 3 (HPF3) contains two viral gly

18 The envelope of human parainfluenza virus type 3 (HPF3) contains two viral gly

19 Entry and fusion of human parainfluenza virus type 3 (HPF3) require the interactio

20 Entry and fusion of human parainfluenza virus type 3 (HPF3) requires interaction o

21 erence have not been characterized for human parainfluenza virus type 3 (HPF3), and the possible role

22 inhibit the neuraminidase activity of human parainfluenza virus type 3 (HPF3).

23 ur previous observation on the role of human parainfluenza virus type 3 (HPIV 3) C protein in the tra

24 The RNA polymerase complex of human parainfluenza virus type 3 (HPIV 3), a member of the fam

25 paramyxovirus simian virus 5 (SV5) and human parainfluenza virus type 3 (HPIV-3) fusion (F) proteins

26 A full-length clone of the human parainfluenza virus type 3 (HPIV-3) genome (called pHPIV

27 Human parainfluenza virus type 3 (hPIV-3) is a clinically sign

28 Human parainfluenza virus type 3 (HPIV-3) is an airborne patho

29 Human parainfluenza virus type 3 (HPIV-3) is an airborne patho

30 es, respiratory syncytial virus (RSV), human parainfluenza virus type 3 (HPIV-3), and measles virus (

31 on factor, with the cis-acting RNAs of human parainfluenza virus type 3 (HPIV3) and packaging of thes

32 valent live attenuated vaccine against human parainfluenza virus type 3 (HPIV3) and respiratory syncy

33 respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are major pediatric r

34 respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are major viral agent

35 SV), human metapneumovirus (hMPV), and human parainfluenza virus type 3 (hPIV3) are responsible for t

36 Respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are the first and sec

37 Respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are two major causes

38 The genomic promoter of human parainfluenza virus type 3 (HPIV3) contains multiple cis

39 The human parainfluenza virus type 3 (HPIV3) fusion (F) and hemagg

40 Human parainfluenza virus type 3 (HPIV3) genome RNA is transcr

41 genes, of a gene cassette encoding the human parainfluenza virus type 3 (HPIV3) hemagglutinin-neurami

42 t also the receptor interaction of the human parainfluenza virus type 3 (HPIV3) hemagglutinin-neurami

43 plementation to follow the dynamics of human parainfluenza virus type 3 (HPIV3) HN/F pairs in living

44 , participates in the transcription of human parainfluenza virus type 3 (HPIV3) in vitro.

45 We demonstrate that human parainfluenza virus type 3 (HPIV3) induces incomplete au

46 Human parainfluenza virus type 3 (HPIV3) infection causes seve

47 Human parainfluenza virus type 3 (HPIV3) is one of the major c

48 It was previously reported that human parainfluenza virus type 3 (HPIV3) multiplication was in

49 onnected to the stalk region of either human parainfluenza virus type 3 (HPIV3) or Nipah virus recept

50 We have analyzed the human parainfluenza virus type 3 (HPIV3) P protein and deletio

51 binant virus rHPIV3-N(B), a version of human parainfluenza virus type 3 (HPIV3) that is attenuated du

52 against Ebola virus (EV), recombinant human parainfluenza virus type 3 (HPIV3) was modified to expre

53 rt here that for three paramyxoviruses-human parainfluenza virus type 3 (HPIV3), a major cause of low

54 Human parainfluenza virus type 3 (HPIV3), a paramyxovirus, is

55 monkeys 100- to 1,000-fold compared to human parainfluenza virus type 3 (HPIV3), and the Ka strain al

56 common pediatric respiratory pathogen, human parainfluenza virus type 3 (HPIV3), as a vaccine vector

57 encephalomyocarditis virus (EMCV) and human parainfluenza virus type 3 (HPIV3), induced down-regulat

58 ing the childhood respiratory pathogen human parainfluenza virus type 3 (HPIV3), possess an envelope

59 For human parainfluenza virus type 3 (HPIV3), the effects of speci

60 For human parainfluenza virus type 3 (HPIV3), the receptor binding

61 aminidase (HN) surface glycoprotein of human parainfluenza virus type 3 (HPIV3).

62 intranasal paediatric vaccine against human parainfluenza virus type 3 (HPIV3).

63 s), Newcastle disease virus (NDV), and human parainfluenza virus type 3 (HPIV3).

64 s virus of the Arenaviridae family and human parainfluenza virus type 3 of the Paramyxoviridae family

65 paramyxoviruses, Sendai virus (SN) and human parainfluenza virus type 3 (PI3), was constructed and co

66 tory syncytial virus (RSV) and one strain of parainfluenza virus type 3 (PIV-3) was determined.

67 respiratory syncytial virus (RSV) and human parainfluenza virus type-3 (PIV-3) mediate virus entry a

68 nd attenuation (att) phenotypes of the human parainfluenza virus type 3 (PIV3) cp45 live attenuated v

69 In this study, a chimeric bovine/human (b/h) parainfluenza virus type 3 (PIV3) expressing the human P

70 The recent recovery of human parainfluenza virus type 3 (PIV3) from cDNA, together wi

71 Parainfluenza virus type 3 (PIV3) infection led to laryn

72 Parainfluenza virus type 3 (PIV3) infections are a major

73 Parainfluenza virus type 3 (PIV3) is major pathogen of c

74 Two parainfluenza virus type 3 (PIV3) vaccine candidates-cp4

75 During a phase 2 trial of parainfluenza virus type 3 (PIV3) vaccine, sequential se

76 Recombinant human parainfluenza virus type 3 (PIV3) was used as a vector t

77 r the ability to inhibit the growth of human parainfluenza virus type 3 (PIV3), a nonsegmented negati

78 We have previously demonstrated that parainfluenza virus type 3 (PIV3), a significant respira

79 Respiratory syncytial virus (RSV), parainfluenza virus type 3 (PIV3), and rhinovirus (RV) 1

80 A live attenuated bovine parainfluenza virus type 3 (PIV3), harboring the fusion

81 A live attenuated chimeric bovine/human parainfluenza virus type 3 (rB/HPIV3) was developed prev

82 Recombinant bovine/human parainfluenza virus type 3 (rB/HPIV3), a recombinant bov

83 We constructed a human recombinant parainfluenza virus type 3 (rPIV3) that expresses enhanc

84 minidase abolished infection of HAE by human parainfluenza virus type 3, this treatment did not signi

85 vaccine for respiratory syncytial virus and parainfluenza virus type 3, two major causes of severe r

86 protective efficacy of an aerosolized human parainfluenza virus type 3-vectored vaccine that express

87 viruses, including the human pathogen human parainfluenza virus type 3, yet these compounds by thems